US dermatologists’ perceptions and experience with Sotyktu likely impacting their take on the entire TYK2 class for the treatment of plaque psoriasis

Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) — While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call, practicing dermatologists in Spherix…

When Bristol Myers Squibb announced that Sotyktu, a drug developed for the treatment of plaque psoriasis, did not meet growth expectations during their Q3 earnings call, there was a lot of buzz within the dermatology community. US dermatologists who had experience with Sotyktu began to reassess their opinions on the entire TYK2 class of drugs.

Many dermatologists had high hopes for Sotyktu, as it was expected to be a game-changer in the treatment of plaque psoriasis. However, its failure to meet growth expectations left them disappointed and questioning the effectiveness of other drugs in the TYK2 class.

How will this affect me?

If you are currently using or considering using a TYK2 inhibitor for the treatment of plaque psoriasis, the news about Sotyktu may impact your decision-making process. It’s important to stay informed and consult with your dermatologist to determine the best course of treatment for your condition.

How will this affect the world?

The disappointment surrounding Sotyktu’s performance could lead to a shift in the development and approval of new drugs in the TYK2 class. Pharmaceutical companies may take a more cautious approach in bringing these drugs to market, leading to delays in potentially life-changing treatments for patients with plaque psoriasis.

Conclusion

In conclusion, the underperformance of Sotyktu has had ripple effects in the dermatology community, causing US dermatologists to reevaluate their opinions on the entire TYK2 class of drugs. It’s important for both patients and healthcare providers to stay informed and be cautious when considering treatments in this class.